Clinical outcome of patients with differentiated thyroid cancer and raised antithyroglobulin antibody levels: a retrospective study

Table 1 Descriptive characteristics of the study patients (N = 76)

Variables	Mean	Median	Percentile (Q1, Q3)
Age (years) at diagnosis	35.71 ± 14.01	34	25, 45
Time between Surgery and RIT	3.64 ± 1.65	3.0	3, 4.8
RIT (mCi)	66.05 ± 41.12	60.0	30,100
Tg Baseline^a	5.98 ± 16.78	0.27	20, 2.80
Tg after RIT^a	0.66 ± 1.24	0.20	0.20, 0.79
TgAb (baseline)^b	713.29 ± 1073.6	166.50	70, 675.3
TgAb after RIT^b	420.23 ± 830.56	103.0	10,339.5
TgAb (% change, Baseline-early follow up)	−34.29 ± 68.62	−47.57	−78.97, −11.96
TgAb (final)^b	450.42 ± 1185.20	53.0	10, 245.5
TgAb (% change, Baseline-last follow up)	−52.62 ± 53.16	−73.48	−86.90, −33.40
Follow up Duration (months)	58.74 ± 26.26	55	42.30, 71.8

RIT High dose Radiodiodine Therapy, Tg Serum Thyroglobulin, TgAb Serum Antithyroglobulin antibody
^aTg level expressed in ng/dl
^bTgAb level expressed in IU/ml

ISSN: 1756-6614